EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer - PubMed (original) (raw)
. 2014 Jul 10;8(1):204-16.
doi: 10.1016/j.celrep.2014.05.045. Epub 2014 Jun 19.
Affiliations
- PMID: 24953652
- DOI: 10.1016/j.celrep.2014.05.045
Free article
EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer
Zhen Ning Wee et al. Cell Rep. 2014.
Free article
Abstract
Although small-molecule targeting of EZH2 appears to be effective in lymphomas carrying EZH2 activating mutations, finding similar approaches to target EZH2-overexpressing epithelial tumors remains challenging. In MYC-driven, but not PI3K-driven prostate cancer, we show that interferon-γ receptor 1 (IFNGR1) is directly repressed by EZH2 in a MYC-dependent manner and is downregulated in a subset of metastatic prostate cancers. EZH2 knockdown restored the expression of IFNGR1 and, when combined with IFN-γ treatment, led to strong activation of IFN-JAK-STAT1 tumor-suppressor signaling and robust apoptosis. Pharmacologic depletion of EZH2 by the histone-methylation inhibitor DZNep mimicked the effects of EZH2 knockdown on IFNGR1 induction and delivered a remarkable synergistic antitumor effect with IFN-γ. In contrast, although they efficiently depleted histone Lysine 27 trimethylation, EZH2 catalytic inhibitors failed to mimic EZH2 depletion. Thus, EZH2-inactivated IFN signaling may represent a therapeutic target, and patients with advanced prostate cancer driven by MYC may benefit from the combination of EZH2 and IFN-γ-targeted therapy.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
- Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T, Ma A, Jin J, Iseki T, Nakaseko C, Iwama A. Rizq O, et al. Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. doi: 10.1158/1078-0432.CCR-16-2735. Epub 2017 May 10. Clin Cancer Res. 2017. PMID: 28490465 Free PMC article. - The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.
Li Z, Wang Y, Qiu J, Li Q, Yuan C, Zhang W, Wang D, Ye J, Jiang H, Yang J, Cheng J. Li Z, et al. Oncotarget. 2013 Dec;4(12):2532-49. doi: 10.18632/oncotarget.1503. Oncotarget. 2013. PMID: 24345883 Free PMC article. - Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.
Kuser-Abali G, Alptekin A, Cinar B. Kuser-Abali G, et al. Epigenetics. 2014 Apr;9(4):634-43. doi: 10.4161/epi.27957. Epub 2014 Feb 27. Epigenetics. 2014. PMID: 24499724 Free PMC article. - EZH2 as a potential target in cancer therapy.
McCabe MT, Creasy CL. McCabe MT, et al. Epigenomics. 2014 Jun;6(3):341-51. doi: 10.2217/epi.14.23. Epigenomics. 2014. PMID: 25111487 Review. - EZH2, an epigenetic driver of prostate cancer.
Yang YA, Yu J. Yang YA, et al. Protein Cell. 2013 May;4(5):331-41. doi: 10.1007/s13238-013-2093-2. Epub 2013 Apr 30. Protein Cell. 2013. PMID: 23636686 Free PMC article. Review.
Cited by
- EZH2-Myc Hallmark in Oncovirus/Cytomegalovirus Infections and Cytomegalovirus' Resemblance to Oncoviruses.
El Baba R, Herbein G. El Baba R, et al. Cells. 2024 Mar 19;13(6):541. doi: 10.3390/cells13060541. Cells. 2024. PMID: 38534385 Free PMC article. Review. - Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells.
Jing ZL, Liu GL, Zhou N, Xu DY, Feng N, Lei Y, Ma LL, Tang MS, Tong GH, Tang N, Deng YJ. Jing ZL, et al. Sci Rep. 2024 Mar 13;14(1):6053. doi: 10.1038/s41598-024-56681-3. Sci Rep. 2024. PMID: 38480774 Free PMC article. - Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review.
Kouroukli O, Bravou V, Giannitsas K, Tzelepi V. Kouroukli O, et al. Cancers (Basel). 2024 Feb 16;16(4):805. doi: 10.3390/cancers16040805. Cancers (Basel). 2024. PMID: 38398199 Free PMC article. Review. - WSB1 Involvement in Prostate Cancer Progression.
Boldrini L, Bardi M. Boldrini L, et al. Genes (Basel). 2023 Jul 29;14(8):1558. doi: 10.3390/genes14081558. Genes (Basel). 2023. PMID: 37628609 Free PMC article. - Simultaneous administration of EZH2 and BET inhibitors inhibits proliferation and clonogenic ability of metastatic prostate cancer cells.
Negri A, Marozzi M, Trisciuoglio D, Rotili D, Mai A, Rizzi F. Negri A, et al. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2163242. doi: 10.1080/14756366.2022.2163242. J Enzyme Inhib Med Chem. 2023. PMID: 36629431 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous